Tirzepatide Cuts Meal Calories by 59% in Just 3 Weeks, Brain Scans Reveal Why

Tirzepatide — the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist marketed as Mounjaro and Zepbound — produces some of the largest weight losses ever recorded in a pharmacotherapy trial, yet the behavioral and neurological mechanisms driving that weight loss have remained poorly understood. This 6-week phase 1 mechanistic trial, published in Nature Medicine, was designed to fill that gap by rigorously characterizing tirzepatide's early effects on energy intake, appetite, ingestive behavior, and brain activity in adults with overweight or obesity.

The study randomized 114 non-diabetic adults (mean BMI 36.2 kg/m²; 85% female) 1:1:1 to blinded once-weekly tirzepatide (dose-escalated to 10 mg by week 6), blinded placebo, or open-label once-daily liraglutide (dose-escalated to 1.8 mg). The primary outcome was change in energy intake during a standardized ad libitum lunch meal test at week 3. Secondary outcomes included fasting and postprandial appetite by visual analog scale (VAS), food cravings (Food Craving Inventory, FCQ-S), disinhibition, dietary restraint, power of food scale (susceptibility to the food environment), and BOLD fMRI responses to food cue photographs assessed in a fasted state.

The primary result was unambiguous: tirzepatide reduced meal-test energy intake by 523 kcal from baseline, while placebo participants were essentially unchanged (+11 kcal), yielding a treatment difference of −534 kcal (95% CI −668 to −400, P < 0.0001). Using mixed-model repeated measures, the week-3 difference versus placebo was −525 kcal (−59.1% relative reduction) and the difference versus liraglutide was −233 kcal (P = 0.0004), demonstrating tirzepatide's superiority over the selective GLP-1 RA. By week 6, tirzepatide had reduced intake by 658 kcal (−72.4% from baseline), further widening the gap. Liraglutide produced a meaningful but smaller reduction of approximately 299 kcal at week 3 (−31.5%). Body weight fell by roughly 3.5 kg with tirzepatide versus near-zero with placebo at week 3.

On secondary behavioral outcomes, tirzepatide significantly decreased fasting overall appetite, hunger, prospective food consumption, and desire for sweet, salty, and fatty foods, while increasing satiety and fullness versus placebo at week 3. Critically, tirzepatide reduced food cravings and susceptibility to food cues in the environment (Power of Food Scale), and decreased disinhibition (tendency to overeat) — but did not affect dietary restraint, suggesting the drug reduces the biological drive to eat rather than increasing willpower or cognitive control over eating.

The fMRI findings provided novel neurobiological insight. While tirzepatide did not statistically significantly alter BOLD activation to a broad aggregated category of highly palatable foods at week 3, it did significantly reduce activation in the medial frontal and cingulate gyri, orbitofrontal cortex (OFC), and hippocampus specifically in response to high-fat, high-sugar food photos. These regions are central to hedonic food valuation, reward anticipation, and food memory — suggesting tirzepatide may reduce the motivational salience of highly palatable foods at the neural level. This brain-behavior link offers a plausible mechanistic explanation for why patients on tirzepatide report reduced cravings and eat substantially less without feeling deprived. The lack of effect on dietary restraint further supports the interpretation that tirzepatide works by dampening appetitive drive rather than enhancing top-down inhibition.